Etanercept

• CAS Number: 185243-69-0

Etanercept is a drug that is used for the treatment of rheumatic diseases and psoriasis. It is a genetically engineered protein that binds entzündungsinduzierende cytokines and thus inactivated. Etanercept was developed by Amgen and is distributed in Germany, Austria and Switzerland by the pharmaceutical company Pfizer under the brand name Enbrel ® and is subject to medical prescription.

Structure

Etanercept is a genetically engineered fusion protein in Ovarialzelllinien Chinese hamster (CHO cells) is produced. It is a dimeric chimeric protein consisting of the extracellular ligand binding domain of human tumor necrosis factor receptor 2 ( TNFR2/p75 ) is connected to the Fc subunit of the human IgG1 antibody. Etanercept contains 934 amino acids and has a molecular mass of about 150 kDa.

Pharmacology

Mechanism of Action

Etanercept has the ligand binding domain of human tumor necrosis factor receptor 2 Thanks to this ligand-binding domain, it is able to bind the proinflammatory cytokine tumor necrosis factor ( TNF ) and lymphotoxin ( TNFβ ). Tumor necrosis factor and lymphotoxin are proinflammatory cytokines that bind to two different cell-bound receptors: the p55 and p75 tumor necrosis factor - receptor (TNFR ). The bound of etanercept tumor necrosis factor can no longer bind to its natural, located on the cell membrane receptor and thus do not trigger inflammation. Is a balance ( competition ) between the binding of tumor necrosis factor to etanercept or the receptor.

TNF antibody and latent tuberculosis

Since Etanercerpt can affect immune responses and reappearance among other latent tuberculosis under treatment, the treatment must be preceded by a test for TB, which must be negative.